Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07196644 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
A Phase 2 study of Solid Tumors Harboring MET Amplification, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT07196644: Recruiting Phase 2 study of Solid Tumors Harboring MET Amplification, sponsored by AbbVie.
NCT07196644 is a Phase 2 study of Solid Tumors Harboring MET Amplification that is actively recruiting participants, run by AbbVie. The registered enrollment target is 125 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07196644, a Phase 2 study of Solid Tumors Harboring MET Amplification, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 125 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 55 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as part of the 61.5 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Primary Outcome
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG Telisotuzumab Adizutecan
Study Locations (20)
California
- City of Hope National Medical Center /ID# 275613 - Duarte
- Valkyrie Clinical Trials /ID# 275547 - Los Angeles
Illinois
- Northwestern University Feinberg School of Medicine /ID# 276436 - Chicago
- University of Chicago Medical Center /ID# 275342 - Chicago
Texas
- The University of Texas MD Anderson Cancer Center /ID# 275663 - Houston
- South Texas Accelerated Research Therapeutics (START) /ID# 276608 - San Antonio
Tel Aviv
- The Chaim Sheba Medical Center /ID# 274342 - Ramat Gan
- Tel Aviv Sourasky Medical Center /ID# 274344 - Tel Aviv
Other
- Hadassah Medical Center-Hebrew University /ID# 274343 - Jerusalem
- Rabin Medical Center. /ID# 274341 - Petah Tikva
Connecticut
- Yale University School of Medicine /ID# 275978 - New Haven
Florida
- Florida Cancer Specialists - North /ID# 277137 - St. Petersburg
Michigan
- START Midwest /ID# 276603 - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-10-29 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
What NCT07196644 shows while recruiting
NCT07196644 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Solid Tumors Harboring MET Amplification appearing as the primary indexed condition, and to 1 intervention - of which Telisotuzumab Adizutecan is the first listed.
NCT07196644 names 20 study sites across 15 states, led by California, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT07196644 about?
NCT07196644 is a clinical study titled "A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan". Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of ...
What is the current status of trial NCT07196644?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2025-10-29. Estimated completion is 2030-12.
What conditions does trial NCT07196644 study?
This clinical trial studies the following conditions: Solid Tumors Harboring MET Amplification.
What interventions are being tested in trial NCT07196644?
The interventions under investigation include: Telisotuzumab Adizutecan (DRUG).
Who is sponsoring clinical trial NCT07196644?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07196644 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07196644's enrollment target sits among peer trials
125 558th of 2000 higher than 1,437 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI